F-Prime Capital

F-Prime Capital is a venture capital firm established in 1969 and headquartered in Cambridge, Massachusetts, with additional offices in San Francisco and London. It is part of the Fidelity Investments family, which has a long history of supporting entrepreneurs. F-Prime Capital focuses its investments on companies in North America and Europe, specializing in sectors such as healthcare, life sciences, therapeutics, fashion, medtech, health information technology and services, and technology. The firm emphasizes a hands-on approach, leveraging its deep industry expertise and extensive relationships to assist entrepreneurs in building significant companies. F-Prime Capital operates without the pressures of external fundraising, allowing it to concentrate on identifying and nurturing promising ventures.

Abdul Abdirahman

Principal

Jessica Alston

Partner

Nikhil Ananth

Senior Associate

Hannah Arnold

Venture Partner

Raj Basak

Associate

Sam Bisbee

Venture Partner

Eric Blatte

Venture Partner

Carl Byers

Partner

Kevin Chu

Principal

Lucille Conroy

Senior Associate

Shervin Ghaemmagham

Operating Partner

Shervin Ghaemmaghami

Operating Partner

Benjamin Gorman

Venture Partner

Ben Gorman

Principal

Sarah Lamont

Senior Associate

Erica Lee

Senior Associate

Connie Li

Associate

Muzammil Mansuri

Venture Partner

Julia McDowell

Venture Partner

Betsy Mule

Senior Associate

Sandor Palfy

Venture Partner

Sachin Patodia

Partner

Cameron Raglin

Associate

Brett J. Rome

Venture Partner

Mihir Shah

Venture Partner

Siyu Shi Ph.D

Associate

Nihal Sinha

Partner

Anastasiya Sybirna

Senior Associate

Martin Taylor Ph.D

Principal

Jennifer Uhrig

Senior Managing Director

Bala Varadhan

Principal

Mona Vernon

Venture Partner

Stacie Weninger Ph.D

President, FBRI

M. Jackson Wilkinson

Venture Partner and Operating Partner

Alex Wong

Associate

Rocio Wu

Principal

Chong Xu

Partner

Brian Yordy

Principal

Tristan Zajonc

Venture Partner

Michael Zheng

Venture Partner

Past deals in Health Care

Rippl Care

Series A in 2024
Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.

HiLabs

Series B in 2024
HiLabs is a developer of a healthcare data mining platform that aims to enhance data-driven decision-making within healthcare organizations. Recognizing that these organizations possess invaluable domain knowledge, HiLabs provides tools that enable them to harness this expertise alongside their data. The platform employs artificial intelligence to allow healthcare professionals to intuitively explore their data, interact with visualizations, customize dashboards, and generate new attributes. This empowers users to independently uncover novel insights and better understand client health data, ultimately facilitating more effective healthcare management and decision-making.

Devoted

Series E in 2023
Devoted Health, established in 2017 and headquartered in Newton, Massachusetts, specializes in providing comprehensive healthcare solutions for Medicare beneficiaries in the United States. The company offers Medicare Advantage plans, along with personalized care through dedicated health guides, both in-person and virtually. Devoted Health aims to improve the health and well-being of older Americans by combining access to top local providers, virtual and in-home care through Devoted Medical, and advanced technology to deliver tailored healthcare experiences.

Firefly Health

Venture Round in 2022
Firefly Health, Inc. is a Massachusetts-based company that develops an artificial intelligence-driven platform to connect patients with healthcare professionals. Founded in 2016, it focuses on providing primary healthcare services that emphasize accessibility and quality. The platform allows users to navigate their health while offering care for common conditions such as back pain, stomach flu, and women's health issues. Firefly Health utilizes a virtual-first approach, enabling patients to access live video appointments with primary care physicians without membership fees. This model facilitates continuous and intelligent care, empowering patients to make informed health choices and allowing clinicians to deliver consistent and proactive support.

Rippl Care

Seed Round in 2022
Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.

Invetx

Series B in 2022
Invetx, Inc. is a biotechnology company focused on developing protein-based therapeutics for animal health care and veterinary medicine. Based in Boston, Massachusetts, Invetx's team comprises veterinary scientists and clinicians dedicated to discovering and creating biotherapeutics for both pets and farm animals. The company aims to enhance health outcomes in the animal health industry by leveraging biopharma technologies, supported by a network of experts in animal and human health. Through its innovative platform, Invetx is committed to advancing a portfolio of therapies and technologies designed to improve animal care and well-being.

Leyden Labs

Series B in 2022
Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.

Patina Health

Series A in 2021
Patina is a healthcare provider focused on enhancing the aging experience for older adults and their families. The company has developed a care model that prioritizes the unique needs and values of this demographic. By offering personalized and on-demand services, Patina aims to create a healthcare experience that is both human-centered and supportive. This approach allows families to actively participate in the care of their loved ones, ensuring that older adults receive the attention and respect they deserve as they navigate the challenges of aging. Patina's mission is to empower individuals to live their best lives and maintain their dignity as they age.

Stride Health

Series C in 2021
Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The company provides a range of affordable health coverage options, including dental plans, doctor visits, and prescription insurance. By simplifying the enrollment process, Stride Health enables users to quickly select their most cost-effective health plans while also offering assistance from personal advisors to help navigate any complexities. Founded in 2013 and based in San Francisco, California, Stride Health was previously known as Covered, Inc. The company's mission is to make health insurance more accessible and manageable for those who may not have traditional employment benefits.

Carrot Fertility

Series C in 2021
Carrot Fertility, Inc. specializes in providing comprehensive fertility benefits services to employers, supporting employees throughout their fertility healthcare journey on a global scale. The company's offerings include services such as egg freezing, in vitro fertilization, adoption, donor and gestational carrier services, as well as a premium pharmacy experience for fertility medications through Carrot Rx. Additionally, Carrot Pregnancy provides virtual access to experts and on-demand doctor-approved content, while the Carrot Card allows employees to use a flexible debit card for their fertility-related expenses. By customizing these benefits, Carrot Fertility aims to deliver financial, medical, and emotional support for individuals pursuing parenthood. Founded in 2015 and headquartered in San Francisco, California, the company also maintains offices in Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.

Orient Speech Therapy

Series C in 2021
Orient Speech Therapy Center is a professional organization focused on enhancing children's speech and mental development. It specializes in providing speech and language therapy services for children with speech disorders, including those with autism. The center offers early screening, clinical diagnosis, and therapeutic interventions to support improved communication skills. To facilitate this development, Orient Speech Therapy has designed comprehensive curriculums, including the Star Curriculum, which targets children's speech, social skills, phonics, and oral muscle exercises. Through these tailored programs, the center aims to help children overcome communication challenges and foster their overall growth.

Firefly Health

Series B in 2021
Firefly Health, Inc. is a Massachusetts-based company that develops an artificial intelligence-driven platform to connect patients with healthcare professionals. Founded in 2016, it focuses on providing primary healthcare services that emphasize accessibility and quality. The platform allows users to navigate their health while offering care for common conditions such as back pain, stomach flu, and women's health issues. Firefly Health utilizes a virtual-first approach, enabling patients to access live video appointments with primary care physicians without membership fees. This model facilitates continuous and intelligent care, empowering patients to make informed health choices and allowing clinicians to deliver consistent and proactive support.

Leyden Labs

Series A in 2021
Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.

J-Pharma

Series D in 2021
J-Pharma is a pharmaceutical company focused on developing novel drugs through a human-genomic approach, specifically targeting cell membrane transporters associated with various diseases. The company aims to create selective agents for treating conditions such as cancer by developing anti-cancer drugs and PET diagnostic agents that interact with transporters like LAT1, which are linked to cancer cell growth. J-Pharma's research emphasizes the importance of understanding drug transporters to enhance the pharmacokinetics of new drug candidates. By discovering key transporters within the human body, J-Pharma seeks to advance diagnostic methods and improve treatment options, thereby contributing to global health and enhancing the quality of life for aging populations in industrialized countries.

Carrot Fertility

Series B in 2020
Carrot Fertility, Inc. specializes in providing comprehensive fertility benefits services to employers, supporting employees throughout their fertility healthcare journey on a global scale. The company's offerings include services such as egg freezing, in vitro fertilization, adoption, donor and gestational carrier services, as well as a premium pharmacy experience for fertility medications through Carrot Rx. Additionally, Carrot Pregnancy provides virtual access to experts and on-demand doctor-approved content, while the Carrot Card allows employees to use a flexible debit card for their fertility-related expenses. By customizing these benefits, Carrot Fertility aims to deliver financial, medical, and emotional support for individuals pursuing parenthood. Founded in 2015 and headquartered in San Francisco, California, the company also maintains offices in Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.

PatientPing

Series C in 2020
PatientPing, Inc. is a health technology company that has established a national care coordination network designed to connect healthcare providers with real-time notifications whenever patients receive care. The network encompasses a diverse group of healthcare personnel, including physicians, nurses, case managers, and care coordinators across various settings such as hospitals, emergency departments, and skilled nursing facilities. PatientPing offers technology solutions tailored to Accountable Care Organizations (ACOs) and other healthcare providers, facilitating improved collaboration and information sharing. One of its key tools, Spotlights, leverages real-time data to identify utilization and performance trends in patient care. Founded in 2013 and headquartered in Boston, Massachusetts, PatientPing operates as a subsidiary of SVB Leerink Holdings LLC and maintains a strategic partnership with MedAllies, Inc. By fostering connections among care teams, PatientPing aims to enhance the quality and efficiency of healthcare delivery, ultimately leading to better patient outcomes.

NFlection Therapeutics

Series A in 2020
NFlection Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of targeted therapies for rare disorders. Based in Wayne, Pennsylvania, the company primarily addresses conditions such as neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks like keratinocytic epidermal nevi and nevus sebaceous. NFlection specializes in treatments that target the Ras/Raf/MEK/ERK signaling pathway, which is often aberrantly activated in these disorders. One of its notable developments includes a soft mitogen-activated protein kinase (MEK) formulated as a cosmetically elegant gel for topical application, allowing for localized treatment while minimizing systemic side effects typically associated with orally administered MEK inhibitors. Founded in 2014, NFlection Therapeutics aims to improve patient outcomes through innovative therapeutic solutions.

Arvelle Therapeutics

Series A in 2020
Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.

Rallybio

Series B in 2020
Rallybio is a clinical-stage biopharmaceutical company focused on developing transformative therapies for patients with severe and rare disorders. Founded in 2018 and based in New Haven, Connecticut, the company is advancing its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a serious condition that can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's portfolio includes a range of promising product candidates targeting rare diseases across various therapeutic areas, including hematology, immuno-inflammation, maternal-fetal health, and metabolic disorders. The company's efforts are supported by a team of experienced professionals with extensive expertise in biopharma research and development.

Devoted

Series C in 2020
Devoted Health, established in 2017 and headquartered in Newton, Massachusetts, specializes in providing comprehensive healthcare solutions for Medicare beneficiaries in the United States. The company offers Medicare Advantage plans, along with personalized care through dedicated health guides, both in-person and virtually. Devoted Health aims to improve the health and well-being of older Americans by combining access to top local providers, virtual and in-home care through Devoted Medical, and advanced technology to deliver tailored healthcare experiences.

Iora Health

Series F in 2020
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Firefly Health

Series A in 2019
Firefly Health, Inc. is a Massachusetts-based company that develops an artificial intelligence-driven platform to connect patients with healthcare professionals. Founded in 2016, it focuses on providing primary healthcare services that emphasize accessibility and quality. The platform allows users to navigate their health while offering care for common conditions such as back pain, stomach flu, and women's health issues. Firefly Health utilizes a virtual-first approach, enabling patients to access live video appointments with primary care physicians without membership fees. This model facilitates continuous and intelligent care, empowering patients to make informed health choices and allowing clinicians to deliver consistent and proactive support.

Quartet Health

Series D in 2019
Quartet Health is a New York-based company that develops a cloud-based platform designed to enhance communication and collaboration between medical providers and behavioral health providers for patient care. Founded in 2014, Quartet's platform works with health plans and systems to deliver actionable insights and reports on behavioral health conditions, aiming to improve patient outcomes. The platform also offers tools for patient self-management and ensures that mental health care is tailored to individual preferences and clinical needs, while being integrated with the broader healthcare experience and insurance coverage.

LunaDNA

Venture Round in 2019
LunaDNA is a community-owned platform that facilitates the sharing of health and DNA data for medical research. Founded by the creators of Illumina, a leader in DNA sequencing, LunaDNA addresses the issue of siloed genomic data by providing individuals with a compelling incentive to share their health information. Participants are rewarded with shares in the database, allowing them to benefit from the profits generated by medical research and discoveries. This model not only empowers users to contribute their health records, genomic data, and personal health experiences but also fosters a sense of community ownership. As researchers pay to access the data for their studies, the proceeds are distributed back to the community, akin to dividends. By prioritizing privacy and trust, LunaDNA aims to increase participation in genomic research while facilitating advancements in healthcare that can ultimately save lives.

Structure Therapeutics

Series A in 2019
Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for chronic diseases with significant unmet medical needs. Utilizing advanced computational and structure-based technology, the company designs orally available small molecules that aim to overcome the limitations of traditional biologic and peptide drugs. Its lead product candidate, GSBR-1290, is a small molecule agonist targeting the glucagon-like peptide-1 receptor, which is relevant for treating type-2 diabetes and obesity. Additionally, Structure Therapeutics is advancing other oral therapeutics targeting G-protein-coupled receptors for conditions such as pulmonary and cardiovascular diseases, including candidates ANPA-0073 and LTSE-2578. The company combines expertise in drug design and development to create differentiated and effective treatments that can have a profound impact on patient care.

Nebula Genomics

Series A in 2018
Nebula Genomics is a company that focuses on human genome sequencing and health data, aiming to create a comprehensive online marketplace for genomic information. Founded in 2016 by Harvard genomics pioneer George Church and his colleagues, the company is headquartered in San Francisco, California, with additional offices in Boston, Massachusetts. Nebula Genomics utilizes blockchain technology to empower consumers by allowing them to maintain control over their genomic data and receive compensation for its use. The platform aggregates extensive genetic information, enabling researchers to analyze data for accelerated drug development and personalized medicine. The company’s DNA sequencing technology covers all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, facilitating in-depth genetic analysis and variant exploration.

Compass Therapeutics

Series A in 2018
Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Iora Health

Series E in 2018
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Quartet Health

Series C in 2018
Quartet Health is a New York-based company that develops a cloud-based platform designed to enhance communication and collaboration between medical providers and behavioral health providers for patient care. Founded in 2014, Quartet's platform works with health plans and systems to deliver actionable insights and reports on behavioral health conditions, aiming to improve patient outcomes. The platform also offers tools for patient self-management and ensures that mental health care is tailored to individual preferences and clinical needs, while being integrated with the broader healthcare experience and insurance coverage.

Nebula Genomics

Seed Round in 2018
Nebula Genomics is a company that focuses on human genome sequencing and health data, aiming to create a comprehensive online marketplace for genomic information. Founded in 2016 by Harvard genomics pioneer George Church and his colleagues, the company is headquartered in San Francisco, California, with additional offices in Boston, Massachusetts. Nebula Genomics utilizes blockchain technology to empower consumers by allowing them to maintain control over their genomic data and receive compensation for its use. The platform aggregates extensive genetic information, enabling researchers to analyze data for accelerated drug development and personalized medicine. The company’s DNA sequencing technology covers all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, facilitating in-depth genetic analysis and variant exploration.

Orchard Therapeutics

Series B in 2017
Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.

Orient Speech Therapy

Series B in 2017
Orient Speech Therapy Center is a professional organization focused on enhancing children's speech and mental development. It specializes in providing speech and language therapy services for children with speech disorders, including those with autism. The center offers early screening, clinical diagnosis, and therapeutic interventions to support improved communication skills. To facilitate this development, Orient Speech Therapy has designed comprehensive curriculums, including the Star Curriculum, which targets children's speech, social skills, phonics, and oral muscle exercises. Through these tailored programs, the center aims to help children overcome communication challenges and foster their overall growth.

Devoted

Series A in 2017
Devoted Health, established in 2017 and headquartered in Newton, Massachusetts, specializes in providing comprehensive healthcare solutions for Medicare beneficiaries in the United States. The company offers Medicare Advantage plans, along with personalized care through dedicated health guides, both in-person and virtually. Devoted Health aims to improve the health and well-being of older Americans by combining access to top local providers, virtual and in-home care through Devoted Medical, and advanced technology to deliver tailored healthcare experiences.

Stride Health

Series B in 2017
Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The company provides a range of affordable health coverage options, including dental plans, doctor visits, and prescription insurance. By simplifying the enrollment process, Stride Health enables users to quickly select their most cost-effective health plans while also offering assistance from personal advisors to help navigate any complexities. Founded in 2013 and based in San Francisco, California, Stride Health was previously known as Covered, Inc. The company's mission is to make health insurance more accessible and manageable for those who may not have traditional employment benefits.

Compass Therapeutics

Series A in 2017
Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Celes Care

Seed Round in 2017
Celes Care is India's first online health clinic dedicated to women's health, based in Hyderabad. The platform provides an accessible and affordable service that connects women with expert female doctors for consultations on various health topics, including pregnancy care, nutrition, wellness, and general health. By offering a virtual clinic, Celes Care ensures that women receive personalized and comprehensive healthcare guidance in a compassionate manner. The service aims to facilitate quick access to medical advice, allowing users to connect with doctors within a minute, thereby enhancing the overall healthcare experience for women.

Abelian Therapeutics

Seed Round in 2017
Abelian Therapeutics is a biotechnology company which engages in harnessing factors in brain disease.

Iora Health

Series D in 2016
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Orchard Therapeutics

Series A in 2016
Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.

Quartet Health

Series B in 2016
Quartet Health is a New York-based company that develops a cloud-based platform designed to enhance communication and collaboration between medical providers and behavioral health providers for patient care. Founded in 2014, Quartet's platform works with health plans and systems to deliver actionable insights and reports on behavioral health conditions, aiming to improve patient outcomes. The platform also offers tools for patient self-management and ensures that mental health care is tailored to individual preferences and clinical needs, while being integrated with the broader healthcare experience and insurance coverage.

Cipla Health

Venture Round in 2016
Cipla Health is a pharmaceutical company dedicated to developing and commercializing consumer healthcare products. It specializes in creating over-the-counter medicines, including nicotine replacement therapy gum, cough lozenges, immunity booster supplements, and pregnancy care medicines. By focusing on these areas, Cipla Health aims to enhance the healthcare experience for patients and consumers alike. Its commitment to providing accessible and effective healthcare solutions underscores its role in the wellness sector.

PatientPing

Series A in 2015
PatientPing, Inc. is a health technology company that has established a national care coordination network designed to connect healthcare providers with real-time notifications whenever patients receive care. The network encompasses a diverse group of healthcare personnel, including physicians, nurses, case managers, and care coordinators across various settings such as hospitals, emergency departments, and skilled nursing facilities. PatientPing offers technology solutions tailored to Accountable Care Organizations (ACOs) and other healthcare providers, facilitating improved collaboration and information sharing. One of its key tools, Spotlights, leverages real-time data to identify utilization and performance trends in patient care. Founded in 2013 and headquartered in Boston, Massachusetts, PatientPing operates as a subsidiary of SVB Leerink Holdings LLC and maintains a strategic partnership with MedAllies, Inc. By fostering connections among care teams, PatientPing aims to enhance the quality and efficiency of healthcare delivery, ultimately leading to better patient outcomes.

Cogent Biosciences

Series B in 2015
Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

VitalWare

Series A in 2015
VitalWare, LLC is a provider of revenue cycle software as a service (SaaS) solutions tailored for healthcare organizations. Founded in 2011 and based in Yakima, Washington, the company offers a comprehensive suite of tools designed to enhance the efficiency of healthcare documentation, coding, billing, and auditing processes. Its products include VitalCDM, which aids in charge management; VitalCDI, which enhances clinical documentation; and iDocuMint, a web-based tool that streamlines the documentation process. Additional offerings such as VitalIntegrity, VitalIntelligence, and VitalKnowledge support compliance with regulatory requirements and improve financial outcomes for healthcare providers. With a client base of over 590 healthcare institutions, VitalWare focuses on delivering solutions that provide visibility in Chargemaster management, charge capture, and regulatory compliance, ultimately helping organizations achieve better reimbursement and operational improvements.

Stride Health

Series A in 2015
Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The company provides a range of affordable health coverage options, including dental plans, doctor visits, and prescription insurance. By simplifying the enrollment process, Stride Health enables users to quickly select their most cost-effective health plans while also offering assistance from personal advisors to help navigate any complexities. Founded in 2013 and based in San Francisco, California, Stride Health was previously known as Covered, Inc. The company's mission is to make health insurance more accessible and manageable for those who may not have traditional employment benefits.

Quartet Health

Series A in 2015
Quartet Health is a New York-based company that develops a cloud-based platform designed to enhance communication and collaboration between medical providers and behavioral health providers for patient care. Founded in 2014, Quartet's platform works with health plans and systems to deliver actionable insights and reports on behavioral health conditions, aiming to improve patient outcomes. The platform also offers tools for patient self-management and ensures that mental health care is tailored to individual preferences and clinical needs, while being integrated with the broader healthcare experience and insurance coverage.

Iora Health

Series C in 2015
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Stride Health

Seed Round in 2015
Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The company provides a range of affordable health coverage options, including dental plans, doctor visits, and prescription insurance. By simplifying the enrollment process, Stride Health enables users to quickly select their most cost-effective health plans while also offering assistance from personal advisors to help navigate any complexities. Founded in 2013 and based in San Francisco, California, Stride Health was previously known as Covered, Inc. The company's mission is to make health insurance more accessible and manageable for those who may not have traditional employment benefits.

Orient Speech Therapy

Series A in 2015
Orient Speech Therapy Center is a professional organization focused on enhancing children's speech and mental development. It specializes in providing speech and language therapy services for children with speech disorders, including those with autism. The center offers early screening, clinical diagnosis, and therapeutic interventions to support improved communication skills. To facilitate this development, Orient Speech Therapy has designed comprehensive curriculums, including the Star Curriculum, which targets children's speech, social skills, phonics, and oral muscle exercises. Through these tailored programs, the center aims to help children overcome communication challenges and foster their overall growth.

Cogent Biosciences

Series A in 2014
Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Iora Health

Series B in 2013
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Iora Health

Venture Round in 2011
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.